267 related articles for article (PubMed ID: 29696833)
21. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
22. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
Fleischmann R; Kremer J; Cush J; Schulze-Koops H; Connell CA; Bradley JD; Gruben D; Wallenstein GV; Zwillich SH; Kanik KS;
N Engl J Med; 2012 Aug; 367(6):495-507. PubMed ID: 22873530
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
Strand V; Mysler E; Moots RJ; Wallenstein GV; DeMasi R; Gruben D; Soma K; Iikuni N; Smolen JS; Fleischmann R
RMD Open; 2019; 5(2):e001040. PubMed ID: 31673419
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
Li ZG; Liu Y; Xu HJ; Chen ZW; Bao CD; Gu JR; Zhao DB; An Y; Hwang LJ; Wang L; Kremer J; Wu QZ
Chin Med J (Engl); 2018 Nov; 131(22):2683-2692. PubMed ID: 30425195
[TBL] [Abstract][Full Text] [Related]
25. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
Chen DY; Hsu PN; Tang CH; Claxton L; Valluri S; Gerber RA
J Med Econ; 2019 Aug; 22(8):777-787. PubMed ID: 30982378
[No Abstract] [Full Text] [Related]
26. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
[TBL] [Abstract][Full Text] [Related]
27. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
Pérez-Román DI; Ortiz-Haro AB; Ruiz-Medrano E; Contreras-Yáñez I; Pascual-Ramos V
Rheumatol Int; 2018 Apr; 38(4):599-606. PubMed ID: 29264637
[TBL] [Abstract][Full Text] [Related]
28. Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
Chopra A; Shobha V; Chandrashekara S; Veeravalli SCM; Sharma R; Rao UR; Pandya S; Wagh S; Kadel JK; Thorat AV; Adhav C; Santos Estrella P; Yu W; Kwok K; Wouters A
Int J Rheum Dis; 2020 Jul; 23(7):882-897. PubMed ID: 32478474
[TBL] [Abstract][Full Text] [Related]
29. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B
Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
[TBL] [Abstract][Full Text] [Related]
30. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
[TBL] [Abstract][Full Text] [Related]
31. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
Strand V; van Vollenhoven RF; Lee EB; Fleischmann R; Zwillich SH; Gruben D; Koncz T; Wilkinson B; Wallenstein G
Rheumatology (Oxford); 2016 Jun; 55(6):1031-41. PubMed ID: 26929445
[TBL] [Abstract][Full Text] [Related]
32. Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months.
Bykerk VP; Lee EB; van Vollenhoven R; Gruben DC; Fallon L; Woolcott JC; Keystone E
Arthritis Care Res (Hoboken); 2022 Jan; 74(1):131-141. PubMed ID: 34057820
[TBL] [Abstract][Full Text] [Related]
33. Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients.
Mori S; Yoshitama T; Ueki Y
Intern Med; 2018 Mar; 57(5):663-670. PubMed ID: 29151519
[TBL] [Abstract][Full Text] [Related]
34. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
Dikranian AH; Gonzalez-Gay MA; Wellborne F; Álvaro-Gracia JM; Takiya L; Stockert L; Paulissen J; Shi H; Tatulych S; Curtis JR
RMD Open; 2022 May; 8(1):. PubMed ID: 35577477
[TBL] [Abstract][Full Text] [Related]
36. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
[TBL] [Abstract][Full Text] [Related]
37. Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis.
Conaghan PG; Østergaard M; Troum O; Bowes MA; Guillard G; Wilkinson B; Xie Z; Andrews J; Stein A; Chapman D; Koenig A
Arthritis Res Ther; 2019 Oct; 21(1):214. PubMed ID: 31639034
[TBL] [Abstract][Full Text] [Related]
38. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
[TBL] [Abstract][Full Text] [Related]
39. Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.
Rendas-Baum R; Kosinski M; Singh A; Mebus CA; Wilkinson BE; Wallenstein GV
Rheumatology (Oxford); 2017 Aug; 56(8):1386-1394. PubMed ID: 28460083
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
